l-carnitine injection weight loss randomized controlled trial The Effects of Supplementation on Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Trials L-carnitine ameliorated fasting-induced fatigue, hunger,

Thus, FH offers an important opportunity to target therapies to prevent atherosclerosis (437), but FH remains under recognized with recent evidence suggesting that only 1-10% of subjects with FH have been identified (438)

Andolino C, Cotul EK, Xianyu Z, et al

Branca JJV, Carrino D, Paternostro F, et al

1 Introduction The global prevalence of non-alcoholic fatty liver disease (NAFLD) has shown a consistent upward trend in recent decades, with current estimates indicating an overall prevalence of 30.05% ( In a pivotal 2023 consensus statement, international liver associations proposed redefining disease terminology, replacing NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD) and NASH with metabolic dysfunction-associated steatohepatitis (MASH) ( MASLD pathogenesis involves complex interactions among multiple pathological processes, including excessive fatty acid accumulation, dysregulated inflammatory responses, oxidative stress, and insulin resistance